DATAPHARM A/S: Financial statements 2021
CVR: 72323211
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
DATAPHARM A/S (CVR 72323211) has filed annual accounts for 2021. In 2021, the company reported a net result of DKK 602,055 compared with DKK 304,908 the year before. Equity in the 2021 report amounted to DKK 8,897,670. The solvency ratio was 87.5%.
- Profit/Loss
- DKK 602,055
- Equity
- DKK 8,897,670
- Total Assets
- DKK 10,171,811
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | - | 602 t. | 8.9 mio. | 0 |
| 2020 | - | - | 305 t. | 8.3 mio. | 0 |
| 2019 | - | - | -2.6 mio. | 8 mio. | - |
| 2018 | - | - | -2.5 mio. | 10.5 mio. | - |
| 2017 | - | 1.2 mio. | -2.5 mio. | 13 mio. | 1 |
Official annual report
Find more companies like DATAPHARM A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
DATAPHARM A/S has published its annual report for 2020. The net result was DKK 304,908.
As of April 22, 2021, Dan Asmussen has joined the board of directors of DATAPHARM A/S.
As of April 22, 2021, Jonas Arendal Grønskov has joined the board of directors of DATAPHARM A/S.
As of April 22, 2021, Ute Pørksen has left the board of directors of DATAPHARM A/S.
As of April 22, 2021, Anders Kretzschmar has left the board of directors of DATAPHARM A/S.
About DATAPHARM A/S
DATAPHARM A/S is a Danish company of the type Aktieselskab based in København K, founded in 1983. The company is registered under the industry Computerprogrammering. The management consists of Henrik Bruun. The board consists of Dan Asmussen (chair), Dorte Kamp Teglgård, Jonas Arendal Grønskov and Mia Bendix Andersen. The company is owned by D.A. INVEST OG UDVIKLING A/S. The company has 4 employees (2004). In 2025, the company reported a net result of DKK 657,407 compared with DKK 650,613 the year before. Equity in the 2025 report amounted to DKK 11,750,274.